Tarsus Pharmaceuticals Stock Analysis

Tarsus Stock Analysis Notes

About 91.0% of the company shares are owned by institutional investors. The company has Price/Earnings To Growth (PEG) ratio of 0.28. Tarsus Pharmaceuticals recorded a loss per share of 3.16. The entity had not issued any dividends in recent years. Tarsus Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutic candidates for ophthalmic conditions. Tarsus Pharmaceuticals, Inc. was incorporated in 2016 and is headquartered in Irvine, California. Tarsus Pharmaceuticals operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 46 people. To find out more about Tarsus Pharmaceuticals contact the company at 949 409 1801 or learn more at https://www.tarsusrx.com.

Tarsus Pharmaceuticals Investment Alerts

Tarsus Pharmaceuticals Upcoming and Recent Events

Tarsus Largest EPS Surprises

View All Earnings Estimates

Tarsus Pharmaceuticals Environmental, Social, and Governance (ESG) Scores

Tarsus Pharmaceuticals Thematic Classifications

Tarsus Stock Institutional Investors

Note, although Tarsus Pharmaceuticals' institutional investors appear to be way more sophisticated than retail investors, it remains unclear if professional active investment managers can reliably enhance risk-adjusted returns by an amount that exceeds fees and expenses.

Tarsus Market Capitalization

The company currently falls under 'Mid-Cap' category with a current market capitalization of 1.63 B.

Tarsus Profitablity

The company has Profit Margin (PM) of (1.04) %, which may suggest that it does not properly executes on its current pricing strategies or is unable to control all of the operational costs. This is way below average. Similarly, it shows Operating Margin (OM) of (0.52) %, which suggests for every $100 dollars of sales, it generated a net operating loss of $0.52.

Management Efficiency

Tarsus Pharmaceuticals has return on total asset (ROA) of (0.2726) % which means that it has lost $0.2726 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.5956) %, meaning that it created substantial loss on money invested by shareholders. Tarsus Pharmaceuticals' management efficiency ratios could be used to measure how well Tarsus Pharmaceuticals manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to drop to -0.33 in 2025. Return On Capital Employed is likely to drop to -0.43 in 2025. At this time, Tarsus Pharmaceuticals' Non Current Assets Total are comparatively stable compared to the past year. Other Current Assets is likely to gain to about 9.5 M in 2025, whereas Net Tangible Assets are likely to drop slightly above 114 M in 2025.

Technical Drivers

As of the 27th of February, Tarsus Pharmaceuticals has the Risk Adjusted Performance of (0.02), variance of 9.76, and Coefficient Of Variation of (3,204). In relation to fundamental indicators, the technical analysis model makes it possible for you to check existing technical drivers of Tarsus Pharmaceuticals, as well as the relationship between them. Please validate Tarsus Pharmaceuticals risk adjusted performance, information ratio, as well as the relationship between the Information Ratio and kurtosis to decide if Tarsus Pharmaceuticals is priced more or less accurately, providing market reflects its prevalent price of 42.56 per share. Given that Tarsus Pharmaceuticals has information ratio of (0.03), we advise you to double-check Tarsus Pharmaceuticals's current market performance to make sure the company can sustain itself at a future point.

Tarsus Pharmaceuticals Price Movement Analysis

Tarsus Pharmaceuticals Insider Trading Activities

Tarsus Pharmaceuticals Outstanding Bonds

Tarsus Pharmaceuticals Predictive Daily Indicators

Tarsus Pharmaceuticals Corporate Filings

Tarsus Pharmaceuticals Forecast Models

Tarsus Pharmaceuticals' time-series forecasting models are one of many Tarsus Pharmaceuticals' stock analysis techniques aimed at predicting future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Tarsus Pharmaceuticals' historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.

Stock analysis is the technique used by a trader or investor to examine and evaluate how Tarsus Pharmaceuticals prices is reacting to, or reflecting on a current market direction and economic conditions. It can be used to make informed decisions about market timing, and when buying or selling Tarsus shares will generate the highest return on investment. We also built our stock analysis module to help investors to gain an insight into the world economy as a whole, the stock market, thematic ideas. a specific sector, or an individual Stock such as Tarsus Pharmaceuticals. By using and applying Tarsus Stock analysis, traders can create a robust methodology for identifying Tarsus entry and exit points for their positions.

We track the performance of the top 100 financial experts across various large and mid-size financial boutiques. Tarsus analyst recommendations are determined by taking all analyst recommendations and averaging them as Strong Buy, Buy, Hold, Strong Sell or Sell. There is no one specific way to measure analysis performance other than comparing it to the past results via a very sophisticated attribution analysis. Tarsus analyst consensus and target price projections should be used in combination with other traditional techniques such as stock price forecasting, technical analysis, earnings estimate, and various momentum models.

Tarsus Pharmaceuticals stock analysis indicators help investors evaluate how Tarsus Pharmaceuticals stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing and determine when trading Tarsus Pharmaceuticals shares will generate the highest return on investment. By understating and applying Tarsus Pharmaceuticals stock analysis, traders can identify Tarsus Pharmaceuticals position entry and exit signals to maximize returns.

When running Tarsus Pharmaceuticals' price analysis, check to measure Tarsus Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Tarsus Pharmaceuticals is operating at the current time. Most of Tarsus Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Tarsus Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Tarsus Pharmaceuticals' price. Additionally, you may evaluate how the addition of Tarsus Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.